Biologics License Application submitted to FDA for efbemalenograstim alfa (Ryzneuta) for chemotherapy-induced neutropenia
Phase III trial of this recombinant fusion protein containing G-CSF at the amino terminal and human IgG2-Fc fragment at the carboxyl terminal comparing its efficacy and safety vs. pegfilgrastim met its primary and secondary endpoints.
Source:
Biospace Inc.